ArticlePloS one2010
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review.American journal of public health · 2013Pooled it
- HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.PLoS medicine · 2012Pooled it
- Trial
- Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission.PloS one · 2012Trial
- Trial
- Hepatitis Delta Virus Clade 8 Is the Predominant Clade Circulating in Botswana amongst People Living with HIV.Viruses · 2024Article
- Long-term non-progression and risk factors for disease progression among children living with HIV in Botswana and Uganda: A retrospective cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Addressing an HIV cure in LMIC.Retrovirology · 2021Review
- Diffusions of sound frequencies designed to target dehydrins induce hydric stress tolerance inHeliyon · 2020Article
- High HIV-1 RNA Among Newly Diagnosed People in Botswana.AIDS research and human retroviruses · 2018Article
- Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis.American journal of epidemiology · 2016Article
- Rapid disease progression in HIV-1 subtype C-infected South African women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- The HIV epidemic in Southern Africa - Is an AIDS-free generation possible?Current HIV/AIDS reports · 2014Review
- Sample size considerations in the design of cluster randomized trials of combination HIV prevention.Clinical trials (London, England) · 2014Article
- Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.AIDS research and human retroviruses · 2014Article
- Linkage of viral sequences among HIV-infected village residents in Botswana: estimation of linkage rates in the presence of missing data.PLoS computational biology · 2014Article
- Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Lancet (London, England) · 2013Review
- Intra-host evolutionary rates in HIV-1C env and gag during primary infection.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2013Article
- Overview of the current state of the epidemic.Current HIV/AIDS reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naïve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1-4.2 log(10)) and cART-initiating cohorts (5.1-5.3 log(10)) by about one log(10). The proportion of individuals with high (> or = 50,000 (4.7 log(10)) copies/ml) HIV-1 RNA levels ranged from 24%-28% in the general HIV-positive population cohorts to 65%-83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%-50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load > or = 50,000 (4.7 log(10)) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%-82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified "test-and-treat" strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.